AZD-1305

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameAZD-1305
Drug Alias NameAZD-1305
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPotassium channel blockersSodium channel alpha subunit blockers
TargetsPotassium channelSodium channel alpha subunit
Therapy Area/IndicationsAtrial FlutterAtrial Fibrillation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesSlovakia +[14] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Plc
Active IndicationsN/A
Inactive IndicationsAtrial FlutterAtrial Fibrillation

Other Information

ATC CodeN/A
Related LinksWikipedia